Cilta-cel in R/R MM: ASCO 2024 Updates from CARTITUDE Trials
Hans Lee, MD, discusses recent updates presented at ASCO 2024 surrounding cilta-cel CAR T-cell therapy in relapsed/refractory multiple myeloma.
Video content above is prompted by the following questions:
- Review the recent updates surrounding CAR T-cell therapy in R/R MM:
- CARTITUDE-4 subgroup analysis
- CARTITUDE-2 cohort A expansion subgroup
- CARTITUDE-2 cohort D
- What is the rationale for using CAR T-cell therapy in patients with R/R MM?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
